Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT) the male
hormone that leads to benign prostate growth. By blocking the conversion of testosterone to
DHT, dutasteride could allow bicalutamide to be a more effective anti-androgen thus
prolonging bicalutamide's efficacy.
Inclusion criteria:
- Men ≥40 and ≤90 years of age
- Must have asymptomatic prostate cancer that has progressed during androgen
deprivation therapy (rising PSA). PSA progression must have occurred after first-line
treatment with GnRH analogues ( e. g. leuprolide, goserelin) or orchiectomy. PSA
progression is defined by three rises in PSA each measured at least 4 weeks apart
within the previous year.
- Serum PSA ≥2 and ≤20ng/ml from central laboratory. One PSA retest from central
laboratory is allowed if the value is <2 or >20ng/ml; or if the PSA value is not
consistent with the previous rising PSA values that determined progression while on a
GnRH analogue.
- Serum Testosterone <50ng/ml from central laboratory.
- Non-metastatic prostate cancer as confirmed on prior bone scan performed within 8
weeks of screening.
- Expected survival ≥ 2 years
- ECOG Performance status 0, 1, or 2
Exclusion criteria:
- Additional hormonal therapy (excluding the current use of a GnRH analogue) within the
past 6 months of:
- Estrogens (e. g. megestrol, medroxyprogesterone, cyproterone, DES)
- Drugs with antiandrogenic properties (e. g., spironolactone if >50mg/day, flutamide,
bicalutamide*, ketoconazole**, progestational agents)
*The use of an antiandrogen during GnRH analogue induction for <6 weeks is
acceptable, but none within the 3 months prior to study entry.
**The use of topical ketoconazole is permitted prior to and during the study. NOTE:
Use of dietary and herbal supplements (e. g., selenium, Vitamin E, saw palmetto),
excluding daily vitamins, during the study is discouraged, but not prohibited. All
dietary and herbal supplement usage will be recorded in the eCRF.
- Treatment with oral glucocorticoids during the 3 months prior to randomization or
expectation of their use during the study.
- Prior chemotherapy for prostate cancer. (prior prostatectomy or radiotherapy to the
prostate are allowed)
- Prostate surgery including TUNA, TURP, TUIP, laser treatment, thermotherapy, balloon
dilatation, prosthesis, and cryosurgical ablation within 2 months prior to
enrollment.
- Current and/or previous use of the following medications:
- Finasteride (Proscar, Propecia), or Dutasteride (GI198745, AVODART) exposure within 6
months prior to study entry
- Anabolic steroids (within 6 months prior to study entry)
- Participation in any investigational or marketed drug trial within the 30 days prior
to the first dose of study drug or anytime during the study period.
- Any unstable serious co-existing medical condition(s) including but not limited to
myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias,
clinically evident congestive heart failure, or cerebrovascular accident within 6
months prior to Screening visit; uncontrolled diabetes; or peptic ulcer disease which
is uncontrolled by medical management.
- Abnormal liver function test greater than 1. 5 times the upper limit of normal for
alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline
phosphatase [ALP] or bilirubin.
- Serum creatinine >2. 0 times the upper limit of normal.
- History of another malignancy within five years that could affect the treatment of
prostate cancer or survival of the subject.
- History or current evidence of drug or alcohol abuse within the last 12 months.
- History of any illness (including psychiatric) that, in the opinion of the
investigator, might confound the results of the study or pose additional risk to the
subject.
- Known hypersensitivity to any 5 alpha-reductase inhibitor or to any drug chemically
related to dutasteride.
GSK Investigational Site, Quebec G1R 2J6, Canada
GSK Investigational Site, Homewood, Alabama 35209, United States
GSK Investigational Site, Huntsville, Alabama 35801, United States
GSK Investigational Site, Calgary, Alberta T2V 1P9, Canada
GSK Investigational Site, Little Rock, Arkansas 72205, United States
GSK Investigational Site, Surrey, British Columbia V3V 1N1, Canada
GSK Investigational Site, Victoria, British Columbia V8T 5G1, Canada
GSK Investigational Site, Anaheim, California 92801, United States
GSK Investigational Site, Fresno, California 93720, United States
GSK Investigational Site, San Bernardino, California 92404, United States
GSK Investigational Site, San Diego, California 92101, United States
GSK Investigational Site, Denver, Colorado 80211, United States
GSK Investigational Site, Washington, District of Columbia 20307, United States
GSK Investigational Site, Aventura, Florida 33180, United States
GSK Investigational Site, Daytona Beach, Florida 32114, United States
GSK Investigational Site, Orlando, Florida 32803, United States
GSK Investigational Site, Galesburg, Illinois 61401, United States
GSK Investigational Site, Evansville, Indiana 47713, United States
GSK Investigational Site, Fort Wayne, Indiana 46825, United States
GSK Investigational Site, Jeffersonville, Indiana 47130, United States
GSK Investigational Site, Overland Park, Kansas 66211, United States
GSK Investigational Site, New Orleans, Louisiana 70112, United States
GSK Investigational Site, Shreveport, Louisiana 71106, United States
GSK Investigational Site, Annapolis, Maryland 21401, United States
GSK Investigational Site, Watertown, Massachusetts 02472, United States
GSK Investigational Site, Chaska, Minnesota 55318, United States
GSK Investigational Site, Minneapolis, Minnesota 55455, United States
GSK Investigational Site, St. Louis, Missouri 63136, United States
GSK Investigational Site, Omaha, Nebraska 68114, United States
GSK Investigational Site, Las Vegas, Nevada 89148, United States
GSK Investigational Site, Albany, New York 12208, United States
GSK Investigational Site, Garden City, New York 11530, United States
GSK Investigational Site, Manhasset, New York 11030, United States
GSK Investigational Site, New York, New York 10016, United States
GSK Investigational Site, Syracuse, New York 13210, United States
GSK Investigational Site, Concord, North Carolina 28025, United States
GSK Investigational Site, Columbus, Ohio 43214, United States
GSK Investigational Site, Barrie, Ontario L4M 7G1, Canada
GSK Investigational Site, Burlington, Ontario L7S 1V2, Canada
GSK Investigational Site, North Bay, Ontario P1B 7K8, Canada
GSK Investigational Site, Oakville, Ontario L6H 3P1, Canada
GSK Investigational Site, Scarborough, Ontario M1S 4V5, Canada
GSK Investigational Site, Sudbury, Ontario P3E 4T3, Canada
GSK Investigational Site, Toronto, Ontario M2K 2W1, Canada
GSK Investigational Site, Toronto, Ontario M4C 5T2, Canada
GSK Investigational Site, Bala Cynwyd, Pennsylvania 19004, United States
GSK Investigational Site, Lancaster, Pennsylvania 17604, United States
GSK Investigational Site, Philadelphia, Pennsylvania 19107, United States
GSK Investigational Site, Greenfield Park, Quebec J4V 2H3, Canada
GSK Investigational Site, Laval, Quebec H7G 2E6, Canada
GSK Investigational Site, Pointe-Claire, Quebec H9R 4S3, Canada
GSK Investigational Site, Myrtle Beach, South Carolina 29572, United States
GSK Investigational Site, Memphis, Tennessee 38119, United States
GSK Investigational Site, Houston, Texas 77074, United States
GSK Investigational Site, San Antonio, Texas 78229, United States
GSK Investigational Site, Norfork, Virginia 23502, United States
GSK Investigational Site, Richmond, Virginia 23235, United States
GSK Investigational Site, Virginia Beach, Virginia 23454, United States
GSK Investigational Site, Williamsburg, Virginia 23185, United States
GSK Investigational Site, Seattle, Washington 98166, United States
GSK Investigational Site, Seattle, Washington 98195-6015, United States
GSK Investigational Site, Milwaukee, Wisconsin 53226, United States
